Pfizer gets its timing right

The pharmaceutical giant is about to capitalise on a major change in the US drug market.

I've been a regular investor in Pfizer, the US-based pharmaceutical stock since the 1980s. Today I see it at a price and range of opportunities that rarely occur together.  To understand why Pfizer is a 'buy' just now takes a little learning – you need to understand the story of 'biosimilars' in world medicine...they are a major breakthrough both for the pharmaceutical industry and for healthcare costs.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles